Does the media prefer SLS or PTGX?

In the previous week, Protagonist Therapeutics had 3 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 14 mentions for Protagonist Therapeutics and 11 mentions for SELLAS Life Sciences Group. Protagonist Therapeutics' average media sentiment score of 1.58 beat SELLAS Life Sciences Group's score of 0.95 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 13 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer SLS or TGTX?

In the previous week, SELLAS Life Sciences Group had 5 more articles in the media than TG Therapeutics. MarketBeat recorded 11 mentions for SELLAS Life Sciences Group and 6 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.97 beat SELLAS Life Sciences Group's score of 0.95 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to QGEN or SLS?

In the previous week, SELLAS Life Sciences Group had 3 more articles in the media than Qiagen. MarketBeat recorded 11 mentions for SELLAS Life Sciences Group and 8 mentions for Qiagen. Qiagen's average media sentiment score of 1.18 beat SELLAS Life Sciences Group's score of 0.95 indicating that Qiagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SELLAS Life Sciences Group 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, APGE or SLS?

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apogee Therapeutics N/A N/A -$255.84M -$4.33 N/A SELLAS Life Sciences Group N/A N/A -$26.86M -$0.23 N/A

Is APGE or SLS more profitable?

Apogee Therapeutics' return on equity of -32.64% beat SELLAS Life Sciences Group's return on equity. Company Net Margins Return on Equity Return on Assets Apogee Therapeutics N/A -32.64% -31.25% SELLAS Life Sciences Group N/A -47.12% -42.63%

Does the media favor APGE or SLS?

In the previous week, SELLAS Life Sciences Group had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 11 mentions for SELLAS Life Sciences Group and 8 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.96 beat SELLAS Life Sciences Group's score of 0.95 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SELLAS Life Sciences Group 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

SELLAS Life Sciences Group (SLS) Competitors

$10.01 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$10.03 +0.02 (+0.19%)

As of 07/31/2026 07:59 PM Eastern

Compare

SLS vs. CRNX, PTGX, TGTX, QGEN, and APGE

Should you buy SELLAS Life Sciences Group stock or one of its competitors? MarketBeat compares SELLAS Life Sciences Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SELLAS Life Sciences Group include Crinetics Pharmaceuticals (CRNX), Protagonist Therapeutics (PTGX), TG Therapeutics (TGTX), Qiagen (QGEN), and Apogee Therapeutics (APGE).

How does SELLAS Life Sciences Group compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and SELLAS Life Sciences Group (NASDAQ:SLS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

In the previous week, Crinetics Pharmaceuticals had 1 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 12 mentions for Crinetics Pharmaceuticals and 11 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.95 beat Crinetics Pharmaceuticals' score of 0.68 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
SELLAS Life Sciences Group	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SELLAS Life Sciences Group has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Crinetics Pharmaceuticals' return on equity of -43.96% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

Crinetics Pharmaceuticals presently has a consensus price target of $81.00, suggesting a potential downside of 3.02%. SELLAS Life Sciences Group has a consensus price target of $10.00, suggesting a potential downside of 0.10%. Given SELLAS Life Sciences Group's stronger consensus rating and higher probable upside, analysts plainly believe SELLAS Life Sciences Group is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Crinetics Pharmaceuticals has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.48, meaning that its share price is 148% more volatile than the broader market.

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

SELLAS Life Sciences Group has lower revenue, but higher earnings than Crinetics Pharmaceuticals. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$18.07M	487.37	-$465.32M	-$5.13	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

Summary

Crinetics Pharmaceuticals beats SELLAS Life Sciences Group on 8 of the 15 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Protagonist Therapeutics?

SELLAS Life Sciences Group (NASDAQ:SLS) and Protagonist Therapeutics (NASDAQ:PTGX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

SELLAS Life Sciences Group has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

SELLAS Life Sciences Group has higher earnings, but lower revenue than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A
Protagonist Therapeutics	$74.06M	118.65	-$130.15M	-$1.81	N/A

SELLAS Life Sciences Group has a beta of 2.48, suggesting that its stock price is 148% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market.

SELLAS Life Sciences Group presently has a consensus price target of $10.00, suggesting a potential downside of 0.10%. Protagonist Therapeutics has a consensus price target of $123.00, suggesting a potential downside of 9.98%. Given SELLAS Life Sciences Group's higher possible upside, research analysts plainly believe SELLAS Life Sciences Group is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

In the previous week, Protagonist Therapeutics had 3 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 14 mentions for Protagonist Therapeutics and 11 mentions for SELLAS Life Sciences Group. Protagonist Therapeutics' average media sentiment score of 1.58 beat SELLAS Life Sciences Group's score of 0.95 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	13 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Protagonist Therapeutics beats SELLAS Life Sciences Group on 10 of the 16 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to TG Therapeutics?

SELLAS Life Sciences Group (NASDAQ:SLS) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

In the previous week, SELLAS Life Sciences Group had 5 more articles in the media than TG Therapeutics. MarketBeat recorded 11 mentions for SELLAS Life Sciences Group and 6 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.97 beat SELLAS Life Sciences Group's score of 0.95 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by insiders. Comparatively, 8.9% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

TG Therapeutics has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A
TG Therapeutics	$616.29M	12.92	$447.18M	$2.86	18.19

TG Therapeutics has a net margin of 65.95% compared to SELLAS Life Sciences Group's net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%
TG Therapeutics	65.95%	88.73%	43.44%

SELLAS Life Sciences Group has a beta of 2.48, meaning that its share price is 148% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market.

SELLAS Life Sciences Group presently has a consensus price target of $10.00, indicating a potential downside of 0.10%. TG Therapeutics has a consensus price target of $58.50, indicating a potential upside of 12.44%. Given TG Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TG Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Summary

TG Therapeutics beats SELLAS Life Sciences Group on 13 of the 15 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Qiagen?

Qiagen (NYSE:QGEN) and SELLAS Life Sciences Group (NASDAQ:SLS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Qiagen presently has a consensus price target of $43.34, suggesting a potential upside of 4.29%. SELLAS Life Sciences Group has a consensus price target of $10.00, suggesting a potential downside of 0.10%. Given Qiagen's stronger consensus rating and higher possible upside, analysts plainly believe Qiagen is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, SELLAS Life Sciences Group had 3 more articles in the media than Qiagen. MarketBeat recorded 11 mentions for SELLAS Life Sciences Group and 8 mentions for Qiagen. Qiagen's average media sentiment score of 1.18 beat SELLAS Life Sciences Group's score of 0.95 indicating that Qiagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SELLAS Life Sciences Group	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.48, suggesting that its stock price is 148% more volatile than the broader market.

Qiagen has a net margin of 19.16% compared to SELLAS Life Sciences Group's net margin of 0.00%. Qiagen's return on equity of 14.40% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

70.0% of Qiagen shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Qiagen has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.10B	4.08	$424.88M	$1.91	21.76
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

Summary

Qiagen beats SELLAS Life Sciences Group on 14 of the 16 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and SELLAS Life Sciences Group (NASDAQ:SLS) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

Apogee Therapeutics has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.48, meaning that its stock price is 148% more volatile than the broader market.

Apogee Therapeutics' return on equity of -32.64% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

In the previous week, SELLAS Life Sciences Group had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 11 mentions for SELLAS Life Sciences Group and 8 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.96 beat SELLAS Life Sciences Group's score of 0.95 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
SELLAS Life Sciences Group	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Apogee Therapeutics currently has a consensus target price of $121.25, indicating a potential downside of 9.57%. SELLAS Life Sciences Group has a consensus target price of $10.00, indicating a potential downside of 0.10%. Given SELLAS Life Sciences Group's stronger consensus rating and higher probable upside, analysts plainly believe SELLAS Life Sciences Group is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Apogee Therapeutics beats SELLAS Life Sciences Group on 8 of the 14 factors compared between the two stocks.

Get SELLAS Life Sciences Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLS vs. The Competition

Export

Metric	SELLAS Life Sciences Group	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.97B	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-43.52	7.38	282.30	24.66
Price / Sales	N/A	1,182.44	561.34	76.65
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	21.76	16.96	10.98	6.07
Net Income	-$26.86M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-7.66%	-1.76%	-0.60%	-0.44%
1 Month Performance	-33.18%	-8.38%	-5.20%	-4.81%
1 Year Performance	503.01%	48.40%	62.01%	18.61%

SELLAS Life Sciences Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLS SELLAS Life Sciences Group	1.1139 of 5 stars	$10.01 flat	$10.00 -0.1%	+503.0%	$1.97B	N/A	N/A	10	Upcoming Earnings Gap Up
CRNX Crinetics Pharmaceuticals	2.1458 of 5 stars	$83.85 +0.1%	$78.27 -6.7%	+200.0%	$8.83B	$18.07M	N/A	210	Upcoming Earnings
PTGX Protagonist Therapeutics	1.5588 of 5 stars	$135.56 -0.4%	$123.00 -9.3%	+153.8%	$8.75B	$46.02M	N/A	120	Positive News Upcoming Earnings
TGTX TG Therapeutics	3.147 of 5 stars	$55.75 -0.5%	$58.50 +4.9%	+48.6%	$8.58B	$616.29M	19.49	290	Gap Up
QGEN Qiagen	3.9249 of 5 stars	$41.05 -0.8%	$43.34 +5.6%	-20.9%	$8.53B	$2.10B	21.44	5,654	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLS) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SELLAS Life Sciences Group (SLS) Competitors

SLS vs. CRNX, PTGX, TGTX, QGEN, and APGE

How does SELLAS Life Sciences Group compare to Crinetics Pharmaceuticals?

Summary

How does SELLAS Life Sciences Group compare to Protagonist Therapeutics?

Summary

How does SELLAS Life Sciences Group compare to TG Therapeutics?

Summary

How does SELLAS Life Sciences Group compare to Qiagen?

Summary

How does SELLAS Life Sciences Group compare to Apogee Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS vs. The Competition

SELLAS Life Sciences Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SELLAS Life Sciences Group (SLS) Competitors

SLS vs. CRNX, PTGX, TGTX, QGEN, and APGE

How does SELLAS Life Sciences Group compare to Crinetics Pharmaceuticals?

Does the media favor CRNX or SLS?

Is CRNX or SLS more profitable?

Do analysts recommend CRNX or SLS?

Which has more volatility & risk, CRNX or SLS?

Do insiders and institutionals have more ownership in CRNX or SLS?

Which has better valuation and earnings, CRNX or SLS?

Summary

How does SELLAS Life Sciences Group compare to Protagonist Therapeutics?

Is SLS or PTGX more profitable?

Which has better earnings & valuation, SLS or PTGX?

Which has more risk and volatility, SLS or PTGX?

Do analysts rate SLS or PTGX?

Does the media prefer SLS or PTGX?

Do institutionals and insiders hold more shares of SLS or PTGX?

Summary

How does SELLAS Life Sciences Group compare to TG Therapeutics?

Does the media prefer SLS or TGTX?

Do institutionals and insiders believe in SLS or TGTX?

Which has preferable valuation & earnings, SLS or TGTX?

Is SLS or TGTX more profitable?

Which has more volatility & risk, SLS or TGTX?

Do analysts recommend SLS or TGTX?

Summary

How does SELLAS Life Sciences Group compare to Qiagen?

Do analysts rate QGEN or SLS?

Does the media refer more to QGEN or SLS?

Which has more risk & volatility, QGEN or SLS?

Is QGEN or SLS more profitable?

Do institutionals & insiders hold more shares of QGEN or SLS?

Which has stronger valuation & earnings, QGEN or SLS?

Summary

How does SELLAS Life Sciences Group compare to Apogee Therapeutics?

Which has higher earnings & valuation, APGE or SLS?

Which has more volatility & risk, APGE or SLS?

Is APGE or SLS more profitable?

Does the media favor APGE or SLS?

Do institutionals & insiders believe in APGE or SLS?

Do analysts prefer APGE or SLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS vs. The Competition

SELLAS Life Sciences Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools